Alzamend Neuro Trading Up 7.1 %
Shares of ALZN opened at $0.24 on Friday. The firm has a market capitalization of $23.14 million, a P/E ratio of -1.41 and a beta of 0.01. Alzamend Neuro has a 12-month low of $0.21 and a 12-month high of $1.50. The firm has a fifty day moving average price of $0.37 and a 200-day moving average price of $0.49.
Institutional Trading of Alzamend Neuro
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Alzamend Neuro by 6,642.3% in the third quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock worth $4,874,000 after acquiring an additional 4,035,028 shares during the period. BlackRock Inc. purchased a new stake in Alzamend Neuro in the third quarter worth about $709,000. Renaissance Technologies LLC purchased a new stake in Alzamend Neuro in the second quarter worth about $56,000. Virtu Financial LLC purchased a new stake in Alzamend Neuro in the fourth quarter worth about $35,000. Finally, HRT Financial LP purchased a new stake in Alzamend Neuro in the fourth quarter worth about $32,000. 6.37% of the stock is owned by hedge funds and other institutional investors.
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- Five stocks we like better than Alzamend Neuro
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 9/11 – 9/15
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.